Featured Research Search Results
Comparing an Experimental Drug Puxi-Sam with Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)
Clinicaltrials.gov identifier:
NCT07044336
Treatment
Phase 3 treatment study for metastatic endometrial cancer
Phase 3
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
Clinicaltrials.gov identifier:
NCT07397338
Treatment
Treatment study for solid tumors with a RAS mutation
Phase 1/2
Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT06841354
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Phase 3
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
Clinicaltrials.gov identifier:
NCT06128551
Treatment
Treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Phase 1/2
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
Clinicaltrials.gov identifier:
NCT06411691
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
Phase 1
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
Clinicaltrials.gov identifier:
NCT05879926
Treatment
Study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
Phase 3
Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab
Clinicaltrials.gov identifier:
NCT05112601
Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker
Phase 2
Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
Clinicaltrials.gov identifier:
NCT05372640
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Phase 1
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Phase 1
Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer
Clinicaltrials.gov identifier:
NCT07140679
Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer
Phase 2
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD
Clinicaltrials.gov identifier:
NCT06580314
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT06958328
Treatment
Radiation treatment study for people with locally advanced pancreatic cancer
Phase 3
A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer
Clinicaltrials.gov identifier:
NCT06952803
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
Phase 3
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Phase 1
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
Phase 3
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
Phase 1
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Phase 1
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer